Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 301 AL 315

From research to clinical practice: DNA methylation signatures as diagnostic tools for Alzheimer's disease

Shimoda N.

Epigenomics. 2026 Mar;18(3):303-310. doi: 10.1080/17501911.2026.2635932. Epub 2026 Feb 23.

Diagnostic Value of Inflammatory Biomarkers in Differentiating Vascular Dementia From Alzheimer's Disease: A Systematic Review and Meta-Analysis

Ling Y, Sun J, Hu L, Zhao M, Chen J, Zheng Y.

Brain Behav. 2026 Apr;16(4):e71341. doi: 10.1002/brb3.71341.

From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study

Gebril NM, Elettreby AM, Younis AH, Moawad MHED, Hafez AM, Sayed GE, Abdelrahman KM, El-Kot SM.

Mol Neurobiol. 2026 May 4;63(1):606. doi: 10.1007/s12035-026-05864-2.

Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: A systematic review

Catino F, Castellana F, Zupo R, Giannoccaro V, Lampignano L, Petrosillo AM, Addabbo F, Sborgia G, Colacicco G, Santoro C, Boero G, Impedovo D, Zheng Y, Sardone R.

Artif Intell Med. 2026 Jul;177:103389. doi: 10.1016/j.artmed.2026.103389. Epub 2026 Mar 23.

Sex differences in the relationship of biomarker change to memory decline in early Alzheimer's disease: an observational cohort study

Sundermann EE, Banks SJ, Bondi MW, Martinez MA, Biegon A, Rotblatt LJ, Hildebrandt T.

Biol Sex Differ. 2026 Jan 16;17(1):38. doi: 10.1186/s13293-025-00820-6.

Molecular and statistical weaknesses of the p-tau217/Aβ(1-42) plasma ratio for alzheimer's diagnosis

Ferré CG, Pallàs M, Franco R.

J Mol Med (Berl). 2026 May 12;104(1):72. doi: 10.1007/s00109-026-02676-8.

The Role of Exosome-miRNA as Biomarkers of Alzheimer's Disease: A Systematic Review of Case-Control and Longitudinal Studies

Zhou H, Liu Y, Li K, Mou S, Cao X, Chen Q.

Actas Esp Psiquiatr. 2026 Apr 15;54(2):556-567. doi: 10.62641/aep.v54i2.2109.

[The Clinical Applicability of Blood Biomarkers for Alzheimer's disease in the Memory Clinic]

Kloppenburg-Lagendijk M, Huitema Y, van Harten A, Hempenius L, Verwey N.

Tijdschr Gerontol Geriatr. 2026 Mar 31;57(1):10-27. doi: 10.54195/tgg24597.

Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025)

Kanoria S, Veitch DP, Miller MJ, Aisen PS, Beckett LA, Green RC, Harvey DJ, Jack CR Jr, Jagust W, Lee EB, Nho K, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC, Mindt MR, Saykin AJ, Shaw LM, Toga AW, Tosun D, Landau SM, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2026 Apr;22(4):e71353. doi: 10.1002/alz.71353.

Progress in Machine Learning-Assisted Biosensors for Alzheimer's Disease

Feng Y, Chen C.

Biosensors (Basel). 2026 Mar 13;16(3):161. doi: 10.3390/bios16030161.

The Role of Magnetic Resonance Spectroscopy (MRS), Diffusion-Tensor-Imaging (DTI) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

Zecca V, Palombelli G, Vanacore N, Canese R.

J Magn Reson Imaging. 2026 Jun;63(6):1509-1545. doi: 10.1002/jmri.70296. Epub 2026 Mar 19.

Precision pathways: optimising amyloid PET for sustainable Alzheimer's disease care

Morbelli SD, Bozzali M, Cagnin A, Cecchin D, Chiti A, Filippi M.

J Neurol. 2026 May 26;273(6):340. doi: 10.1007/s00415-026-13874-2.

Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population

Russell JK, Schlachetzki Z, Rafii MS.

Curr Opin Neurol. 2026 Apr 1;39(2):210-216. doi: 10.1097/WCO.0000000000001461. Epub 2026 Feb 18.

Multi-omics integration reveals shared genetic architecture between metabolic markers and gray matter atrophy in Alzheimer's Disease

Wang P, Wu X, Sun F, Zhang H, Jiang Y, Wang Q, Ding H, Zhou Y, Liu F, Liu H.

J Prev Alzheimers Dis. 2026 Feb;13(2):100452. doi: 10.1016/j.tjpad.2025.100452. Epub 2026 Jan 1.

Consensus statement on the use of Alzheimer's disease biomarkers and anti-amyloid therapies in Hong Kong

Shum CK, Shea YF, Au Yeung TW, Chan CCY, Chan WC, Cheng WK, Cheung NYF, Cho DHY, Chow TK, Fong GCY, Ip BYM, Kwok JSH, Lai BMH, Lam LCW, Lee ATC, Lok CM, Mok KY, Ng DKK, Siu DYW, Yeung PY, Tam SKF.

Hong Kong Med J. 2026 Apr;32(2):144-154. doi: 10.12809/hkmj2514198. Epub 2026 Apr 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias